Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company’s portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company’s web site at www.alteon.com.
- 17 years ago
QualityStocks
Synvista Therapeutics, Inc. (AMEX: SYI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Featured in MiningNewsWire Editorial on Rising Energy Demand and Natural Hydrogen
This article has been disseminated on behalf of MAX Power Mining and may include paid…
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Nu.Q NETs Assay Selected for France’s National Sepsis Detection Initiative
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs…
-
QualityStocksNewsBreaks – New Pacific Metals Corp. (TSX: NUAG) (NYSE American: NEWP) Reports Progress at Bolivian Silver Projects
This article has been disseminated on behalf of New Pacific Metals Corp. and may include paid…